PriceTargets.com logo

Adherex Technologies - FENC Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $15.25
  • Forecasted Upside: 99.35%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 1 Strong Buy Ratings
$7.65 As of 03/19/2026 05:00 PM ET
▲ +0.18 (2.41%)

This chart shows the closing price for FENC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Adherex Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FENC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FENC

Analyst Price Target is $15.25
▲ +99.35% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Adherex Technologies in the last 3 months. The average price target is $15.25, with a high forecast of $18.00 and a low forecast of $13.00. The average price target represents a 99.35% upside from the last price of $7.65.

This chart shows the closing price for FENC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 contributing investment analysts is to moderate buy stock in Adherex Technologies. This rating has held steady since December 2025, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2025
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/19/2025
  • 1 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/17/2026
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2026

Latest Recommendations

  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/12/2026B. Riley FinancialInitiated CoverageBuy$16.00
2/11/2026B. Riley FinancialUpgradeStrong-Buy
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/9/2026Piper SandlerInitiated CoverageOverweight$18.00
12/12/2025Zacks ResearchUpgradeStrong Sell ➝ Hold
10/14/2025Zacks ResearchDowngradeHold ➝ Strong Sell
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/21/2025HC WainwrightReiterated RatingBuy ➝ Buy$13.00
8/15/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
8/15/2025Craig HallumBoost TargetBuy ➝ Buy$13.00 ➝ $14.00
5/20/2025HC WainwrightReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
5/14/2025Craig HallumBoost TargetBuy ➝ Buy$12.00 ➝ $13.00
3/11/2025HC WainwrightReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
3/10/2025WedbushReiterated RatingOutperform$13.00
12/20/2024WedbushReiterated RatingOutperform$13.00
12/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
11/18/2024StephensUpgradeStrong-Buy
11/7/2024WedbushReiterated RatingOutperform$14.00 ➝ $13.00
8/22/2024HC WainwrightLower TargetBuy ➝ Buy$15.00 ➝ $13.00
8/14/2024Craig HallumLower TargetBuy ➝ Buy$17.00 ➝ $15.00
8/13/2024WedbushReiterated RatingOutperform$16.00 ➝ $14.00
5/15/2024Craig HallumLower TargetBuy ➝ Buy$20.00 ➝ $17.00
5/15/2024HC WainwrightLower TargetBuy ➝ Buy$18.00 ➝ $15.00
5/14/2024WedbushReiterated RatingOutperform$16.00
4/4/2024HC WainwrightBoost TargetBuy ➝ Buy$17.00 ➝ $18.00
3/18/2024Craig HallumBoost TargetBuy ➝ Buy$17.00 ➝ $18.00
3/18/2024WedbushReiterated RatingOutperform$16.00
8/4/2023HC WainwrightLower TargetBuy ➝ Buy$18.00 ➝ $17.00
4/6/2023Cantor FitzgeraldBoost TargetOverweight$12.00 ➝ $16.00
3/31/2023HC WainwrightReiterated RatingBuy$18.00
1/26/2023HC WainwrightReiterated RatingBuy$18.00
11/21/2022Cantor FitzgeraldUpgradeNeutral ➝ Overweight$9.00 ➝ $12.00
10/20/2022HC WainwrightBoost TargetBuy$14.00 ➝ $18.00
9/29/2022Maxim GroupBoost Target$10.00 ➝ $15.00
9/26/2022WedbushBoost Target$11.00 ➝ $19.00
9/21/2022WedbushReiterated RatingOutperform$11.00
9/7/2022Capital One FinancialInitiated CoverageOverweight$11.00
8/8/2022Craig HallumReiterated RatingBuy$14.00
4/27/2022WedbushReiterated RatingOutperform
12/1/2021Maxim GroupLower TargetBuy$12.00 ➝ $10.00
11/30/2021Cantor FitzgeraldDowngradeOverweight ➝ Neutral
11/30/2021Craig HallumLower TargetBuy$19.00 ➝ $14.00
6/24/2021HC WainwrightReiterated RatingBuy
6/3/2021HC WainwrightLower TargetBuy$15.00 ➝ $14.00
5/28/2021Maxim GroupReiterated RatingBuy$12.00
4/21/2021Craig HallumInitiated CoverageBuy$17.00
4/19/2021Maxim GroupInitiated CoverageBuy$12.00
(Data available from 3/19/2021 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/21/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/20/2025
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/20/2025
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/19/2025
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2025
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2026
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2026

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Adherex Technologies logo
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
Read More

Today's Range

Now: $7.65
Low: $7.34
High: $7.74

50 Day Range

MA: $7.96
Low: $7.39
High: $8.99

52 Week Range

Now: $7.65
Low: $4.68
High: $9.92

Volume

140,465 shs

Average Volume

136,908 shs

Market Capitalization

$262.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75

Frequently Asked Questions

What sell-side analysts currently cover shares of Adherex Technologies?

The following Wall Street sell-side analysts have issued reports on Adherex Technologies in the last year: B. Riley Financial, Inc., Craig Hallum, HC Wainwright, Piper Sandler, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for FENC.

What is the current price target for Adherex Technologies?

0 Wall Street analysts have set twelve-month price targets for Adherex Technologies in the last year. Their average twelve-month price target is $15.25, suggesting a possible upside of 99.3%. Piper Sandler has the highest price target set, predicting FENC will reach $18.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $13.00 for Adherex Technologies in the next year.
View the latest price targets for FENC.

What is the current consensus analyst rating for Adherex Technologies?

Adherex Technologies currently has 1 sell rating, 1 hold rating, 3 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for FENC.

What other companies compete with Adherex Technologies?

Other companies that are similar to Adherex Technologies include Bicara Therapeutics, ArriVent BioPharma, Olema Pharmaceuticals, Inhibrx Biosciences and CureVac. Learn More about companies similar to Adherex Technologies.

How do I contact Adherex Technologies' investor relations team?

Adherex Technologies' physical mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company's listed phone number is 919-636-4530. The official website for Adherex Technologies is www.fennecpharma.com. Learn More about contacing Adherex Technologies investor relations.